GlassScriptPhysician profile
Michael Robert Ruebhausen
NPI 1942649819
$612.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $354 · 2021: $108 · 2022: $13.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $251.87 | 2020 | |
| Checkpoint Surgical, INC | $73.98 | 2019 | |
| Smith+Nephew, INC. | $69.47 | 2020 | |
| Mentor Worldwide LLC | $53.78 | 2019-2021 | |
| Organogenesis INC. | $36.82 | 2019 | |
| Merz North America, INC. | $35.57 | 2021 | |
| Depuy Synthes Sales INC. | $30.12 | 2021 | |
| Kci USA, INC. | $19.03 | 2020 | |
| Sientra, INC. | $13.93 | 2022 | |
| Allergan, INC. | $13.90 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruebhausen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.